[1]徐一艳,何倩,蔡林康,等.新型减毒HSV-2疫苗 IFN-γ ELISpot检测方法的建立[J].湖北工业大学学报,2024,39(4):57-60.
　XU YiyanHE Qian?CAI Linkang LIU Binlei.Establishment of IFN-γ ELISpot Assay for a NewAttenuated HSV-2 Vaccine[J].,2024,39(4):57-60.
点击复制

新型减毒HSV-2疫苗 IFN-γ ELISpot检测方法的建立()
分享到：

《湖北工业大学学报》[ISSN:1003-4684/CN:42-1752/Z]

卷:
39
期数:
2024年第4期
页码:
57-60
栏目:
出版日期:
2024-08-28

文章信息/Info

Title:
Establishment of IFN-γ ELISpot Assay for a NewAttenuated HSV-2 Vaccine
文章编号:
1003-4684(2024)04-0057-04
作者:
徐一艳1;  何倩2;  蔡林康2;  刘滨磊1
(1 湖北工业大学生物工程与食品学院， 湖北 武汉 430068；2 武汉滨会生物科技股份有限公司，湖北 武汉 430073)
Author(s):
XU Yiyan1HE Qian2?CAI Linkang2 LIU Binlei1
(1 School of Bioengineering and Food, Hubei Univ. of Tech., Wuhan 430068,China；2 Wuhan Binhui Biotechnology Co., Ltd, Wuhan 430073,China)
关键词:
酶联免疫斑点试验;  细胞免疫;  干扰素γ
Keywords:
ELISpot;  cellular immunity;  IFN-γ
分类号:
R392
文献标志码:
A
摘要:
通过比较不同刺激物、细胞培养时间、细胞接种浓度、免疫途径，建立检测新型减毒HSV -2疫苗细胞免疫水平的IFN -γ ELISpot方法。 对C57BL/6小鼠进行减毒HSV -2疫苗免疫，第14天加强免疫，第21天分离小鼠脾脏淋巴细胞，采用IFN -γ ELISpot检测该疫苗的细胞免疫水平。结果表明：最佳实验孔刺激物为紫外灭活30 min、原滴度为108CCID50/mL的疫苗全病毒颗粒，最佳细胞培养时间为24~48 h，最佳细胞接种浓度为3×106cells/mL，最佳免疫途径是皮下注射。实验建立了针对该疫苗的IFN -γ ELISpot方法，为该疫苗提供了一种检测细胞免疫水平的方法。
Abstract:
The IFN -γ ELISpot method was established to detect the cellular immune level of a novel attenuated HSV -2 vaccine by comparing the experimental conditions such as different stimulators, cell culture time, cell inoculation concentration, and immune pathway. C57BL/6 mice were immunized with the novel attenuated HSV -2 vaccine, and strengthened on the 14th day. Spleen lymphocytes were isolated on the 21st day. The cellular immune level of the vaccine was detected by IFN -γ ELISPOT assay. The results show that the optimal stimulator of experimental hole is Ultraviolet inactivation HSV -2 particles (1×108CCID50/mL), the optimal cell culture time is 24 -48 h, the optimal cell concentration is 3×106cells/mL, the optimal immune route is subcutaneous injection. The IFN -γ ELISpot assay for the vaccine was established, which provides a method for detecting the cellular immune level of the vaccine.

参考文献/References:

［1］JAMES C, HARFOUCHE M, WELTON N J, et al. Herpes simplex virus: global infection prevalence and incidence estimates, 2016 [J ]. Bulletin of the World Health Organization, 2020, 98(05): 315 -29. [2 ]FREEMAN E E, WEISS H A, GLYNN J R, et al. Herpes simplex virus 2 infection increases HIV acquisition in men and women: systematic review and meta -analysis of longitudinal studies [J ]. Aids, 2006, 20(01): 73 -83. [3 ]ARORA P, NAGELKERKE N J D, JHA P. A systematic review and meta -analysis of risk factors for sexual transmission of HIV in India [J ]. Plos One, 2012, 7(08)：e44094. [4 ]KOELLE D M, COREY L. Herpes simplex: Insights on pathogenesis and possible vaccines [J ]. Annual Review of Medicine, 2008, 59: 381 -95. [5 ]KIMBERLIN D W, WHITLEY R J, WAN W, et al. Oral Acyclovir Suppression and Neurodevelopment after Neonatal Herpes [J ]. New England Journal of Medicine, 2011, 365(14): 1284 -1292. [6 ]CZERKINSKY C C, NILSSON L A, NYGREN H, et al. A solid -phase enzyme -linked immunospot (ELISpot) assay for enumeration of specific antibody -secreting cells [J ]. Journal of Immunological Methods, 1983, 65(1 -2): 109 -21. [7 ]LEE J Y. Comparison of two commercial interferon -γ assays for diagnosing Mycobacterium tuberculosis infection [J ]. European Respiratory Journal, 2006, 28(01): 24 -30. [8 ]李靖, 董文学, 杨美盼, 等. IFN -γ研究进展与临床应用 [J ]. 卫生职业教育, 2019, 37(23): 3. [9 ]SIOTA M, LIM J B, DANG Y, et al. ELISpot for measuring human immune responses to vaccines [J ]. Expert Review of Vaccines, 2011, 10(03): 299 -306. [10 ] MOODIE Z, HUANG Y D, GU L, et al. Statistical positivity criteria for the analysis of ELISpot assay data in HIV -1 vaccine trials [J ]. Journal of Immunological Methods, 2006, 315(1 -2): 121 -32. [11 ] POSAVAD C M, MAGARET A S, ZHAO L, et al. Development of an interferon -gamma ELISPOT assay to detect human T cell responses to HSV -2 [J ]. Vaccine, 2011, 29(40): 7058 -66. [12 ] 张春涛, 刘春雨, 吴瑜, 等. ELISPOT,MHC肽五聚体和ICCD三种检测特异性细胞免疫应答方法的比较研究 [J ]. 中华实验和临床病毒学杂志, 2006, 20: 3.

备注/Memo

备注/Memo:
［收稿日期］ 20220924［第一作者］ 徐一艳（1997-）， 女， 河南周口人， 湖北工业大学硕士研究生， 研究方向为生物与医药。［通信作者］ 刘滨磊（1962-）， 男， 湖北武汉人， 湖北工业大学教授， 研究方向为生物制药。
更新日期/Last Update: 2024-08-23